Spatial interrogation of biomarkers within the tumour microenvironment provides valuable insight into tumour progression and drug response. Development of reliable multiplex IHC / IF staining assays is however complex, time-consuming, and relies upon antibody suitability. To address this, we aimed to adopt two novel assays; PhenoCodeTM Signature Panels and RNAscope + multiplex IHC, which offer an alternative approach to biomarker discovery and development. PhenoCodeTM Signature Panels greatly reduce panel optimisation times by utilising barcode-based antibody chemistry to apply a single pre-optimised cocktail of six antibodies in one step.RNAscope + multiplex IHC enables the detection of multiple RNA and protein biomarkers on the same tissue section, providing a solution when a suitable antibody cannot be sourced for a particular biomarker. Here we test the robustness of a PhenoCodeTM panel and demonstrate the staining of two RNAscope / protein panels as proof of principle